Menu

American Gene Technologies: Addressing the World’s Endemic Diseases

AGT is developing and commercializing genetic medicines targeting major diseases

Written by

Alumni Ventures

Published on

Alumni Ventures portfolio company American Gene Technologies (AGT) is developing and commercializing genetic medicines targeting major diseases, including HIV/AIDS, phenylketonuria, and hepatocellular carcinoma (liver cancer, or HCC). AGT’s drugs will treat symptomatic disease with the intent to provide durable cures that extend the length and improve the quality of patients’ lives.

About American Gene Technologies

AGT is a biopharmaceutical company developing genetic medicines that meet unmet medical needs in inherited or acquired diseases through the application of viral vector technology.

The company is focused on achieving permanent cures that provide long-term value for patients, society, investors, and donors by developing and testing cutting-edge gene therapies to cure some of humanity’s worst diseases.

Enterprise clients turn to AGT for:
  • Home

    Extensive catalog of patented treatments for diseases

  • Home

    Revolutionary treatment for HIV

  • Home

    Proven expertise in the fields of medicine and gene therapy

  • Home

    Rapid development of drugs to treat inherited diseases

  • Home

    An industry leader in genetic design and development

Meet AGT Founder & CEO Jeff Galvin

Jeff Galvin earned his BA in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience, including founder or executive positions at a variety of Silicon Valley startups.

Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, Jeff retired to become an angel investor in real estate and high tech.

He came out of retirement in 2006 to found and fund AGT after meeting the late Roscoe Brady, who introduced Galvin to tools called “viral vectors” that enable molecular biologists to deliver genetic material into cells. Brady spent more than 50 years at the National Institute of Health conducting pioneering research on hereditary diseases.

Watch an interview with Jeff and AV Managing Partner Greg Baker.

See video policy below.

A Pioneer of New Disease Treatments

AGT’s HIV cure has shown promise in creating a powerful drug that may bring relief to one of society’s most elusive epidemics and prove the efficiency and effectiveness of AGT’s platform technologies to cure dozens of diseases ranging from viruses to cancers.

In 2019, AGT signed a Research Collaboration Agreement with the National Institute of Allergy and Infectious Diseases (part of the NIH). In 2021, AGT announced that clinical trials indicate its HIV cure should be able to create an effective immune response against HIV in the absence of antiretroviral treatment.

AGT has raised over $78 million to date based on the strength of its intellectual property portfolio, the broad market potential of its primary product, and its team’s understanding of disease treatments. Here are aspects of the deal that our team found compelling:

What We Liked About AGT

  • Home

    Unique IP and Tech

    With an estimated value in the billions, AGT’s technology can be applied to a broader set of diseases more efficiently and effectively. The company has 23 patent families in various stages with six granted patents. AGT is working with researchers and experts from top institutions who have the ne
  • Home

    Flagship Products

    The company is developing single treatment cures that can eliminate a lifetime of chronic care symptom management and treatments. Their solutions offer targeted and locally administered therapies that do not cause systemic toxicities, such as chemotherapy. AGT is building a drug-delivery platform to develop a variety of therapeutics and cures for various diseases.
  • Home

    An Established Organization

    AGT has developed significant assets accrued over a decade of development. Ten years of lentiviral vector experience and platform development position the company head and shoulders above its nearest competitors.

How We’re Involved

AV Funds Invested in AGT

Want to learn more?
View all our available funds and secure data rooms, or schedule an intro call.

New to AV?
Sign up and access exclusive venture content.

Contact [email protected] for additional information. To see additional risk factors and investment considerations, visit av-funds.com/disclosures.

Written by

Alumni Ventures

Alumni Ventures is a network-powered VC firm that helps accredited individuals invest in venture capital.

LinkedIn
Twitter
Facebook
Tagged with

Follow us

Follow us

Neither Alumni Ventures nor any of its funds are sponsored by, affiliated with, or otherwise endorsed by any university. For further details see our Legal & Privacy Policy.

Video Policy: By consuming this content I acknowledge that I may be considering an investment with AV funds for my own or my client’s account. I agree that information contained herein may not be relied upon or used for any other purpose. Offers to purchase securities are only made through formal offering documents, which describe risks (which are significant), terms, and other important information that must be considered before an investment decision is made. To see Important Disclosure Information, visit: https://av-funds.com/disclosures.

Testimonial/Endorsement Policy: Testimonials/Endorsements were provided by the participants without compensation, but each participant has a relationship with Alumni Ventures (AV) from which they benefit. All views expressed are the individual’s own and do not represent the experience of all AV fund investors or companies in which AV funds invest. Please note that testimonials are no guarantee of future performance or success. Any provider of an endorsement that is affiliated with a portfolio company Alumni Ventures has received investment funding from AV, and may in the future seek and/or receive additional funding from AV. This circumstance constitutes a conflict of interest. Providers of testimonials or endorsements were not chosen at random or according to any objective basis, but rather on the basis of their relationship with AV.

Investor Portal Update Policy: Investor portfolio data is updated once per quarter in the AV Investor Portal.

Alumni Ventures is America’s largest VC firm for individual investors based on the combination of total capital raised, number of investments, and number of investors of leading VC firms as reported by Pitchbook and other publicly available information reviewed by AV.

(1) Internal Rate of Return (IRR) for AV Funds is net of management fees and incentive allocations applied to amounts distributed to investors, and gross of incentive allocations applicable to unrealized gains on investments held by AV Funds. IRR for AV Funds includes uninvested cash, unrealized investments, and amounts distributed to investors. The IRR shown for the Russell 2000 indices are gross of fees because indices are not managed investments, and it is not possible to invest directly in an index. For additional information see av-funds.com/disclosures. All investment involves risk, including risk of loss. Past performance is not necessarily indicative of future results. For more information on AV Funds’ investment returns, please see here.

Not an offer to sell, or a solicitation of an offer to purchase, any security. Such offers are only made pursuant to the formal offering documents for the fund, that describe the risks (which are significant), terms, and other important information that must be considered before an investment decision is made.
To see additional risk factors and investment considerations, visit: https://av-funds.com/disclosures.

Please click here to view additional investor policies.

© 2024, Alumni Ventures. All rights reserved.